Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-07-16

Gilead Sciences, Inc. (GILD)

Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$28,437,198
Daniel O'Day total, FY2025
70th
CEO pay percentile vs peers
119:1
CEO-to-median pay ratio
92.19%
Say-on-pay support, latest vote
Companies that benchmark against GILD
25 companies name GILD as a compensation peer

Each company listed discloses GILD in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named GILD in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Daniel O'Day$1,795,192$0$15,238,402$4,500,060$4,848,120$0$2,055,424$28,437,198
Chairman and Chief Executive Officer
Dietmar Berger969,2313,000,0006,999,7581,000,0431,603,5940350,25213,922,878
Chief Medical Officer
Johanna Mercier1,182,26904,564,5171,299,9762,150,9010102,9809,300,643
Chief Commercial and Corporate Affairs Officer
Andrew Dickinson1,116,65404,321,7411,299,9761,956,266070,9798,765,616
Chief Financial Officer
Deborah Telman977,33403,071,792900,0650055,4785,004,669
Former Executive Vice President, Corporate Affairs and General Counsel

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY20242025
Daniel O'Day$28,437,198$23,689,392$22,607,690+4,747,806
Dietmar Berger13,922,878
Johanna Mercier9,300,6438,609,0658,586,754+691,578
Andrew Dickinson8,765,6168,109,7588,107,823+655,858
Deborah Telman5,004,669

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Daniel Patrick O'DayDirector2026-03-27D10,000$137$1,368,162CommonForm 4 ↗
Johanna MercierChief Comm & Corp Aff Officer2026-04-15D3,000141422,880CommonForm 4 ↗
Andrew DickinsonChief Financial Officer2026-04-15D3,000141422,880CommonForm 4 ↗
Daniel Patrick O'DayDirector2026-04-28D3,050130396,534CommonForm 4 ↗
Daniel Patrick O'DayDirector2026-04-28D6,950129895,075CommonForm 4 ↗
Ted W. LoveDirector2026-04-30A1,14600CommonForm 4 ↗
Anthony WeltersDirector2026-04-30A4,88400Derivative, Class A CommonForm 4 ↗
Jeffrey A. BluestoneDirector2026-04-30A4,88400Derivative, Class A CommonForm 4 ↗
Kelly A. KramerDirector2026-04-30A4,88400Derivative, Class A CommonForm 4 ↗
Sandra J. HorningDirector2026-04-30A4,88400Derivative, Class A CommonForm 4 ↗
Anthony WeltersDirector2026-04-30A1,14600CommonForm 4 ↗
Harish M. ManwaniDirector2026-04-30D22413129,308CommonForm 4 ↗
Javier J. RodriguezDirector2026-04-30A1,14600CommonForm 4 ↗
Harish M. ManwaniDirector2026-04-30A1,14600CommonForm 4 ↗
Dividend-equivalent accruals2026-04-301,1461 insider, 1 accrual row
Harish M. ManwaniDirector2026-04-30A4,88400Derivative, Class A CommonForm 4 ↗
Javier J. RodriguezDirector2026-04-30A4,88400Derivative, Class A CommonForm 4 ↗
Sandra J. HorningDirector2026-04-30A1,14600CommonForm 4 ↗
Ted W. LoveDirector2026-04-30A4,88400Derivative, Class A CommonForm 4 ↗
Jeffrey A. BluestoneDirector2026-04-30A1,14600CommonForm 4 ↗
Jacqueline K. BartonDirector2026-04-30A1,14600CommonForm 4 ↗
Jacqueline K. BartonDirector2026-04-30A4,88400Derivative, Class A CommonForm 4 ↗
Johanna MercierChief Comm & Corp Aff Officer2026-05-15D8,3741321,107,314CommonForm 4 ↗
Andrew DickinsonChief Financial Officer2026-05-15D3,000132396,810CommonForm 4 ↗
Johanna MercierChief Comm & Corp Aff Officer2026-05-15D25,00000Derivative, Class A CommonForm 4 ↗
Johanna MercierChief Comm & Corp Aff Officer2026-05-15D11,1771311,466,330CommonForm 4 ↗
Johanna MercierChief Comm & Corp Aff Officer2026-05-15D7,7491301,009,629CommonForm 4 ↗
Johanna MercierChief Comm & Corp Aff Officer2026-05-15A25,000671,666,000CommonForm 4 ↗
Johanna MercierChief Comm & Corp Aff Officer2026-05-15D70013392,926CommonForm 4 ↗
Daniel Patrick O'DayDirector2026-06-01D1,038133138,021CommonForm 4 ↗
Daniel Patrick O'DayDirector2026-06-01D3,062132404,843CommonForm 4 ↗
Daniel Patrick O'DayDirector2026-06-01D10,9001311,428,983CommonForm 4 ↗
Johanna MercierChief Comm & Corp Aff Officer2026-06-10D2,796Derivative, Class A CommonForm 4 ↗
Dietmar BergerChief Medical Officer2026-06-10D533Derivative, Class A CommonForm 4 ↗
Daniel Patrick O'DayDirector2026-06-10D8,779Derivative, Class A CommonForm 4 ↗
Andrew DickinsonChief Financial Officer2026-06-10D1,341121162,905CommonForm 4 ↗
Andrew DickinsonChief Financial Officer2026-06-10D2,796Derivative, Class A CommonForm 4 ↗
Dietmar BergerChief Medical Officer2026-06-10D26312131,949CommonForm 4 ↗
Johanna MercierChief Comm & Corp Aff Officer2026-06-10A2,796CommonForm 4 ↗
Dietmar BergerChief Medical Officer2026-06-10A533CommonForm 4 ↗
Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp2026-06-10A589CommonForm 4 ↗
Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp2026-06-10D28312134,379CommonForm 4 ↗
Andrew DickinsonChief Financial Officer2026-06-10A2,796CommonForm 4 ↗
Johanna MercierChief Comm & Corp Aff Officer2026-06-10D1,341121162,905CommonForm 4 ↗
Daniel Patrick O'DayDirector2026-06-10A8,779CommonForm 4 ↗
Daniel Patrick O'DayDirector2026-06-10D4,213121511,795CommonForm 4 ↗
Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp2026-06-10D589Derivative, Class A CommonForm 4 ↗
Johanna MercierChief Comm & Corp Aff Officer2026-06-15D1,070124132,676CommonForm 4 ↗
Johanna MercierChief Comm & Corp Aff Officer2026-06-15D1,480123182,657CommonForm 4 ↗
Johanna MercierChief Comm & Corp Aff Officer2026-06-15D45012556,430CommonForm 4 ↗
Andrew DickinsonChief Financial Officer2026-06-15D3,000125376,200CommonForm 4 ↗
Daniel Patrick O'DayDirector2026-07-01D3,100127393,933CommonForm 4 ↗
Daniel Patrick O'DayDirector2026-07-01D11,9001261,500,467CommonForm 4 ↗
Andrew DickinsonChief Financial Officer2026-07-15D3,000130389,777CommonForm 4 ↗
Johanna MercierChief Comm & Corp Aff Officer2026-07-15D3,000130389,758CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 55 transactions
InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Daniel Patrick O'DayDirector2026-03-27D10,000$137$1,368,162CommonForm 4 ↗
Johanna MercierChief Comm & Corp Aff Officer2026-04-15D3,000141422,880CommonForm 4 ↗
Andrew DickinsonChief Financial Officer2026-04-15D3,000141422,880CommonForm 4 ↗
Daniel Patrick O'DayDirector2026-04-28D3,050130396,534CommonForm 4 ↗
Daniel Patrick O'DayDirector2026-04-28D6,950129895,075CommonForm 4 ↗
Ted W. LoveDirector2026-04-30A1,14600CommonForm 4 ↗
Anthony WeltersDirector2026-04-30A4,88400Derivative, Class A CommonForm 4 ↗
Jeffrey A. BluestoneDirector2026-04-30A4,88400Derivative, Class A CommonForm 4 ↗
Kelly A. KramerDirector2026-04-30A4,88400Derivative, Class A CommonForm 4 ↗
Sandra J. HorningDirector2026-04-30A4,88400Derivative, Class A CommonForm 4 ↗
Anthony WeltersDirector2026-04-30A1,14600CommonForm 4 ↗
Harish M. ManwaniDirector2026-04-30D22413129,308CommonForm 4 ↗
Javier J. RodriguezDirector2026-04-30A1,14600CommonForm 4 ↗
Harish M. ManwaniDirector2026-04-30A1,14600CommonForm 4 ↗
Kelly A. KramerDirector2026-04-30A1,14600Derivative, Class A CommonForm 4 ↗
Harish M. ManwaniDirector2026-04-30A4,88400Derivative, Class A CommonForm 4 ↗
Javier J. RodriguezDirector2026-04-30A4,88400Derivative, Class A CommonForm 4 ↗
Sandra J. HorningDirector2026-04-30A1,14600CommonForm 4 ↗
Ted W. LoveDirector2026-04-30A4,88400Derivative, Class A CommonForm 4 ↗
Jeffrey A. BluestoneDirector2026-04-30A1,14600CommonForm 4 ↗
Jacqueline K. BartonDirector2026-04-30A1,14600CommonForm 4 ↗
Jacqueline K. BartonDirector2026-04-30A4,88400Derivative, Class A CommonForm 4 ↗
Johanna MercierChief Comm & Corp Aff Officer2026-05-15D8,3741321,107,314CommonForm 4 ↗
Andrew DickinsonChief Financial Officer2026-05-15D3,000132396,810CommonForm 4 ↗
Johanna MercierChief Comm & Corp Aff Officer2026-05-15D25,00000Derivative, Class A CommonForm 4 ↗
Johanna MercierChief Comm & Corp Aff Officer2026-05-15D11,1771311,466,330CommonForm 4 ↗
Johanna MercierChief Comm & Corp Aff Officer2026-05-15D7,7491301,009,629CommonForm 4 ↗
Johanna MercierChief Comm & Corp Aff Officer2026-05-15A25,000671,666,000CommonForm 4 ↗
Johanna MercierChief Comm & Corp Aff Officer2026-05-15D70013392,926CommonForm 4 ↗
Daniel Patrick O'DayDirector2026-06-01D1,038133138,021CommonForm 4 ↗
Daniel Patrick O'DayDirector2026-06-01D3,062132404,843CommonForm 4 ↗
Daniel Patrick O'DayDirector2026-06-01D10,9001311,428,983CommonForm 4 ↗
Johanna MercierChief Comm & Corp Aff Officer2026-06-10D2,796Derivative, Class A CommonForm 4 ↗
Dietmar BergerChief Medical Officer2026-06-10D533Derivative, Class A CommonForm 4 ↗
Daniel Patrick O'DayDirector2026-06-10D8,779Derivative, Class A CommonForm 4 ↗
Andrew DickinsonChief Financial Officer2026-06-10D1,341121162,905CommonForm 4 ↗
Andrew DickinsonChief Financial Officer2026-06-10D2,796Derivative, Class A CommonForm 4 ↗
Dietmar BergerChief Medical Officer2026-06-10D26312131,949CommonForm 4 ↗
Johanna MercierChief Comm & Corp Aff Officer2026-06-10A2,796CommonForm 4 ↗
Dietmar BergerChief Medical Officer2026-06-10A533CommonForm 4 ↗
Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp2026-06-10A589CommonForm 4 ↗
Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp2026-06-10D28312134,379CommonForm 4 ↗
Andrew DickinsonChief Financial Officer2026-06-10A2,796CommonForm 4 ↗
Johanna MercierChief Comm & Corp Aff Officer2026-06-10D1,341121162,905CommonForm 4 ↗
Daniel Patrick O'DayDirector2026-06-10A8,779CommonForm 4 ↗
Daniel Patrick O'DayDirector2026-06-10D4,213121511,795CommonForm 4 ↗
Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp2026-06-10D589Derivative, Class A CommonForm 4 ↗
Johanna MercierChief Comm & Corp Aff Officer2026-06-15D1,070124132,676CommonForm 4 ↗
Johanna MercierChief Comm & Corp Aff Officer2026-06-15D1,480123182,657CommonForm 4 ↗
Johanna MercierChief Comm & Corp Aff Officer2026-06-15D45012556,430CommonForm 4 ↗
Andrew DickinsonChief Financial Officer2026-06-15D3,000125376,200CommonForm 4 ↗
Daniel Patrick O'DayDirector2026-07-01D3,100127393,933CommonForm 4 ↗
Daniel Patrick O'DayDirector2026-07-01D11,9001261,500,467CommonForm 4 ↗
Andrew DickinsonChief Financial Officer2026-07-15D3,000130389,777CommonForm 4 ↗
Johanna MercierChief Comm & Corp Aff Officer2026-07-15D3,000130389,758CommonForm 4 ↗
03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Johanna MercierPerformance Share2025-03-10$676,067
Andrew DickinsonPerformance Share2025-03-10638,795
Andrew DickinsonPerformance Share2025-03-101,949,796
Johanna MercierPerformance Share2025-03-101,949,796
Dietmar BergerPerformance Share2025-03-101,500,134
Deborah TelmanPerformance Share2025-03-10399,217
Deborah TelmanPerformance Share2025-03-10422,542
Deborah TelmanPerformance Share2025-03-101,349,860
Deborah TelmanRSU2025-03-107,680900,173
Dietmar BergerRSU2025-03-108,530999,801
Daniel O'DayPerformance Share2025-03-103,66118,30336,6062,145,295
Dietmar BergerOPTION2025-03-1037,7101,000,043
Johanna MercierPerformance Share2025-03-10638,795
Johanna MercierOPTION2025-03-1049,0201,299,976
Dietmar BergerRSU2025-01-0248,9754,499,823
Andrew DickinsonPerformance Share2025-03-10433,292
Johanna MercierRSU2025-03-1011,0901,299,859
Daniel O'DayPerformance Share2025-03-109,60544,95389,9066,749,937
Daniel O'DayRSU2025-03-1038,3954,500,278
Andrew DickinsonRSU2025-03-1011,0901,299,859
Daniel O'DayPerformance Share2025-03-103,14515,72331,4461,842,893
Andrew DickinsonOPTION2025-03-1049,0201,299,976
Deborah TelmanOPTION2025-03-1033,940900,065
Daniel O'DayOPTION2025-03-10169,6904,500,060
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Johanna Mercier$1,299,859$0$1,299,9760.0%
Andrew Dickinson1,299,85901,299,9760.0%
Dietmar Berger5,499,62401,000,0430.0%
Deborah Telman900,1730900,0650.0%
Daniel O'Day4,500,27804,500,0600.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Daniel O'DayRSU38,396$4,712,725
Daniel O'DayPSU58,5507,186,427
Dietmar BergerRSU8,5301,046,972
Andrew DickinsonRSU7,787955,752
Johanna MercierRSU10,1781,249,207
Andrew DickinsonRSU10,1761,248,991
Dietmar BergerOption37,710117.21
Johanna MercierRSU1,740213,568
Andrew DickinsonRSU1,592195,402
Andrew DickinsonRSU29,6703,641,696
Johanna MercierPSU18,4502,264,553
Johanna MercierRSU11,0901,361,187
Johanna MercierRSU7,358903,060
Johanna MercierRSU9,7341,194,751
Johanna MercierPSU7,440913,186
Johanna MercierRSU7,432912,157
Andrew DickinsonRSU5,110627,201
Johanna MercierRSU5,110627,201
Johanna MercierRSU9,6151,180,132
Daniel O'DayRSU24,7093,032,789
Dietmar BergerPSU5,725702,687
Daniel O'DayRSU14,7411,809,310
Daniel O'DayPSU25,7553,161,169
Andrew DickinsonRSU7,432912,157
Johanna MercierRSU7,787955,752
Dietmar BergerRSU48,9756,011,192
Johanna MercierRSU29,6703,641,696
Andrew DickinsonRSU9,6151,180,132
Daniel O'DayRSU85,58010,504,089
Daniel O'DayRSU38,3954,712,602
Daniel O'DayRSU32,2923,963,510
Daniel O'DayRSU30,8873,791,070
Daniel O'DayRSU27,7393,404,626
Daniel O'DayOption169,690117.21
Daniel O'DayRSU21,4412,631,699
Daniel O'DayRSU21,2262,605,285
Andrew DickinsonRSU11,0901,361,187
Andrew DickinsonRSU9,7341,194,751
Andrew DickinsonPSU7,440913,186
Andrew DickinsonRSU7,358903,060
Daniel O'DayOption157,01175.12
Johanna MercierOption49,48375.12
Daniel O'DayOption67,21879.5
Andrew DickinsonOption49,48375.12
Daniel O'DayOption24,95357.92
Andrew DickinsonOption23,30279.5
Johanna MercierOption23,30279.5
Andrew DickinsonOption49,020117.21
Johanna MercierOption49,020117.21
Andrew DickinsonOption9,81557.92
Johanna MercierOption10,73057.92
Daniel O'DayRSU4,047496,729
Andrew DickinsonPSU18,4502,264,553
05

Incentive-plan design — the Compensation Discussion & Analysis

Our executive compensation program is built on the following fundamental principles that we believe are imperative to achieving our mission while also balancing the long-term interests of our stockholders: Pay-for-Performance, Short- and Long-Term Balance, Value Optimization, Market Competitiveness, Stockholder Alignment

CEO STI target (% of salary)150%
CEO LTI target (% of salary)
Independent consultantFW Cook
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-04-30954,325,80577,503,9473,342,32592.19%Passed
20252025-05-07929,612,73989,351,5012,415,14691.23%Passed
20242024-05-08928,702,91578,647,8081,814,60192.19%Passed
20232023-05-03919,145,38279,500,1053,262,91692.04%Passed
20222022-05-04875,824,76274,354,0692,175,53392.17%Passed
20212021-05-12811,920,486120,448,1882,298,93887.08%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-04-3092.19%a
20252025-05-0791.23%b
20242024-05-0892.19%c

a. Approved under the standard stated in the filing — “With respect to Proposal 1, abstentions will have no effect on the outcome of the vote. With respect to Proposals 2-7, abstentions will have the same effect as an "against" vote.”.

b. Approved under the standard stated in the filing — “With respect to Proposal 1, abstentions will have no effect on the outcome of the vote.”.

c. Approved under the standard stated in the filing — “This is known as a "broker non-vote." With respect to Proposal 1, abstentions will have no effect on the outcome of the vote.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)119 : 1
CEO total compensation$28,437,198
Median employee compensation$238,979
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Anthony WeltersIndependent · Lead Independent Director · Compensation and Talent (Chair) · Nominating and Corporate Governance$180,041$149,932$149,989$0$479,962
Kelly A. KramerIndependent · Audit (Chair) · Compensation and Talent137,521149,932149,9890437,442
Sandra J. HorningIndependent · Nominating and Corporate Governance · Science (Chair)132,521149,932149,98901,500433,942
Harish M. ManwaniIndependent · Compensation and Talent · Nominating and Corporate Governance (Chair)132,521149,932149,9890432,442
Jacqueline K. BartonIndependent · Compensation and Talent · Science115,000149,932149,989015,000429,921
Javier J. RodriguezIndependent · Audit · Nominating and Corporate Governance95,000149,932149,989015,000409,921
Ted W. LoveIndependent · Audit · Science95,000149,932149,989015,000409,921
Jeffrey A. BluestoneIndependent · Nominating and Corporate Governance · Science95,000149,932149,989014,860409,781
Daniel P. O'DayEmployee director · Board Chair00000
09

Board fee structure and ownership guideline

Annual cash retainer$75,000
Annual equity retainer$300,000
Per board meeting fee
Committee chair fees (audit / comp / nom-gov)
Stock ownership guideline5x annual cash retainer
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$982,604
Equity awards (grant-date value)$1,199,456
All other compensation$61,360
Total cost of the board$2,243,420

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Gilead Sciences, Inc. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Gilead Sciences, Inc..

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Eli Lilly and Company2025David Ricks$1,700,000$23,325,000$0$6,485,500$36,698,337
2Johnson & Johnson2025Joaquin Duato1,600,00015,028,9485,927,9954,298,70032,758,111
3AbbVie Inc.2025Robert Michael1,700,00013,268,4563,199,1545,200,00032,530,984
4Gilead Sciences, Inc.2025Daniel O'Day1,795,19215,238,4024,500,0604,848,12028,437,198
5Pfizer Inc.2025Albert Bourla1,800,0009,442,7058,998,1415,400,00027,585,301
6Amgen Inc.2025Robert Bradway1,925,40912,599,5895,399,9963,907,00024,693,120
7Biogen Inc.2025Christopher Viehbacher1,727,88518,368,87503,190,87523,646,004
8Bristol Myers Squibb Company2025Christopher Boerner1,586,34616,061,39903,754,68421,879,919
9Vertex Pharmaceuticals Incorporated2025Reshma Kewalramani1,600,00015,002,27004,118,64021,144,261
10Merck & Co., Inc.2025Robert Davis1,645,30212,102,8383,380,0042,326,50020,797,845
11Regeneron Pharmaceuticals, Inc.2025Leonard Schleifer1,979,922003,682,6557,280,549

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Gilead Sciences, Inc.180%PSU 50 · Options 25 · RSU 25Yes — Relative TSRFW Cook
AbbVie Inc.not disclosedPSU 40 · RSU 40 · Options 20Yes — Relative TSRSemler Brossy
Amgen Inc.136.0%PSU 50 · Options 30 · RSU 20Yes — relative TSRFrederic W. Cook & Co., Inc. (FW Cook)
Biogen Inc.127%PSU 60 · RSU 40YesPay Governance
Bristol Myers Squibb Company157.66%PSU 60 · MSU 40Yes — 3-Year Relative TSR CAGRFarient Advisors LLC
Eli Lilly and Company218%PSU 100NoFW Cook
Johnson & Johnsonnot disclosednot disclosednot disclosedSemler Brossy Consulting Group
Merck & Co., Inc.94%PSU 60 · RSU 20 · Options 20Yes — Relative Total Shareholder Return (R-TSR)FW Cook
Pfizer Inc.150%PSU 50 · MSU 50Yes — relative TSR as compared to the NYSE Arca Pharmaceutical Index (DRG Index or DRG)Meridian Compensation Partners, LLC
Regeneron Pharmaceuticals, Inc.155%Options 60 · RSA 40not disclosedPay Governance LLC
Vertex Pharmaceuticals Incorporatednot disclosedPSU 55 · RSU 45Nonot disclosed

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

FAQ

Frequently asked questions

Who was the highest-paid executive at Gilead Sciences, Inc. in fiscal 2025?
The highest-paid executive at Gilead Sciences, Inc. in fiscal 2025 was Daniel O'Day, who served as Chairman and Chief Executive Officer with total compensation of $28,437,198.
How does Gilead Sciences, Inc.'s chief executive pay compare to its disclosed peer group?
The filing shows that Daniel O'Day's pay falls at the 70th percentile of the disclosed peer group.
What is Gilead Sciences, Inc.'s CEO-to-median employee pay ratio?
As disclosed, the CEO-to-median employee pay ratio was 119:1.
How did shareholders vote on Gilead Sciences, Inc.'s executive compensation?
Shareholders approved the executive compensation plan with 92.19% support in the latest vote.
How much does Gilead Sciences, Inc. spend in total on board compensation for fiscal 2025?
The company reported total board compensation for fiscal 2025 was $2,243,420.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Daniel O'DayDEF 14A2026-03-200001308179-26-000106Section “Summary Compensation Table” · page 74. As printed: 28,437,198. Filing ↗machine: t414 · r1 · c29 · span 989582–989592
2Section 01, Dietmar BergerDEF 14A2026-03-200001308179-26-000106Section “Summary Compensation Table” · page 74. As printed: 13,922,878. Filing ↗machine: span 1025472–1025482
3Section 01, Johanna MercierDEF 14A2026-03-200001308179-26-000106Section “Summary Compensation Table” · page 74. As printed: 9,300,643. Filing ↗machine: r7 · c28 · span 1013633–1013642
4Section 01, Andrew DickinsonDEF 14A2026-03-200001308179-26-000106Section “Summary Compensation Table” · page 74. As printed: 8,765,616. Filing ↗machine: r4 · c28 · span 1001036–1001045
5Section 01, Deborah TelmanDEF 14A2026-03-200001308179-26-000106Section “Summary Compensation Table” · page 74. As printed: 5,004,669. Filing ↗machine: r11 · c28 · span 1029136–1029145
6Section 03, Johanna Mercier Performance ShareDEF 14A2026-03-200001308179-26-000106Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t424 · r15 · c45 · span 1155843–1155850
7Section 03, Andrew Dickinson Performance ShareDEF 14A2026-03-200001308179-26-000106Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t424 · r8 · c45 · span 1107790–1107797
8Section 03, Andrew Dickinson Performance ShareDEF 14A2026-03-200001308179-26-000106Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t424 · r10 · c45 · span 1122447–1122456
9Section 03, Johanna Mercier Performance ShareDEF 14A2026-03-200001308179-26-000106Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t424 · r16 · c45 · span 1161480–1161489
10Section 03, Dietmar Berger Performance ShareDEF 14A2026-03-200001308179-26-000106Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t424 · r20 · c45 · span 1185851–1185860
11Section 03, Deborah Telman Performance ShareDEF 14A2026-03-200001308179-26-000106Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t424 · r25 · c45 · span 1220367–1220374
12Section 03, Deborah Telman Performance ShareDEF 14A2026-03-200001308179-26-000106Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t424 · r26 · c45 · span 1226000–1226007
13Section 03, Deborah Telman Performance ShareDEF 14A2026-03-200001308179-26-000106Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t424 · r27 · c45 · span 1231636–1231645
14Section 03, Deborah Telman RSUDEF 14A2026-03-200001308179-26-000106Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t424 · r29 · c45 · span 1242975–1242982
15Section 03, Dietmar Berger RSUDEF 14A2026-03-200001308179-26-000106Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t439 · r21 · c12 · span 1420420–1420425
16Section 03, Daniel O'Day Performance ShareDEF 14A2026-03-200001308179-26-000106Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t424 · r3 · c44 · span 1078272–1078281
17Section 03, Dietmar Berger OPTIONDEF 14A2026-03-200001308179-26-000106Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t409 · r4 · c4 · span 973499–973505
18Section 03, Johanna Mercier Performance ShareDEF 14A2026-03-200001308179-26-000106Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t424 · r14 · c45 · span 1150207–1150214
19Section 03, Johanna Mercier OPTIONDEF 14A2026-03-200001308179-26-000106Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t409 · r3 · c4 · span 970050–970056
20Section 03, Dietmar Berger RSUDEF 14A2026-03-200001308179-26-000106Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t439 · r23 · c13 · span 1427453–1427459
21Section 03, Andrew Dickinson Performance ShareDEF 14A2026-03-200001308179-26-000106Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t424 · r9 · c45 · span 1115118–1115125
22Section 03, Johanna Mercier RSUDEF 14A2026-03-200001308179-26-000106Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t439 · r15 · c13 · span 1403918–1403924
23Section 03, Daniel O'Day Performance ShareDEF 14A2026-03-200001308179-26-000106Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t424 · r4 · c44 · span 1083813–1083822
24Section 03, Daniel O'Day RSUDEF 14A2026-03-200001308179-26-000106Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t424 · r6 · c44 · span 1094895–1094904
25Section 03, Andrew Dickinson RSUDEF 14A2026-03-200001308179-26-000106Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t424 · r12 · c45 · span 1137108–1137117
26Section 03, Daniel O'Day Performance ShareDEF 14A2026-03-200001308179-26-000106Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t424 · r2 · c45 · span 1072720–1072729
27Section 03, Andrew Dickinson OPTIONDEF 14A2026-03-200001308179-26-000106Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t409 · r2 · c4 · span 966851–966857
28Section 03, Deborah Telman OPTIONDEF 14A2026-03-200001308179-26-000106Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t409 · r5 · c4 · span 976670–976676
29Section 03, Daniel O'Day OPTIONDEF 14A2026-03-200001308179-26-000106Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t409 · r1 · c4 · span 963281–963288
30Section 07, pay ratioDEF 14A2026-03-200001308179-26-000106Section “CEO Pay Ratio”. As printed: 119 : 1. Filing ↗machine: span 954130–954138
31Section 08, Anthony WeltersDEF 14A2026-03-200001308179-26-000106Section “Director Compensation”. As printed: 479,962. Filing ↗machine: t249 · r8 · c19 · span 648004–648011
32Section 08, Kelly A. KramerDEF 14A2026-03-200001308179-26-000106Section “Director Compensation”. As printed: 437,442. Filing ↗machine: t249 · r4 · c19 · span 640806–640813
33Section 08, Sandra J. HorningDEF 14A2026-03-200001308179-26-000106Section “Director Compensation”. As printed: 433,942. Filing ↗machine: t249 · r3 · c19 · span 638999–639006
34Section 08, Harish M. ManwaniDEF 14A2026-03-200001308179-26-000106Section “Director Compensation”. As printed: 432,442. Filing ↗machine: t249 · r6 · c19 · span 644422–644429
35Section 08, Jacqueline K. BartonDEF 14A2026-03-200001308179-26-000106Section “Director Compensation”. As printed: 429,921. Filing ↗machine: t249 · r1 · c19 · span 635342–635349
36Section 08, Javier J. RodriguezDEF 14A2026-03-200001308179-26-000106Section “Director Compensation”. As printed: 409,921. Filing ↗machine: t249 · r7 · c19 · span 646237–646244
37Section 08, Ted W. LoveDEF 14A2026-03-200001308179-26-000106Section “Director Compensation”. As printed: 409,921. Filing ↗machine: t249 · r5 · c19 · span 642613–642620
38Section 08, Jeffrey A. BluestoneDEF 14A2026-03-200001308179-26-000106Section “Director Compensation”. As printed: 409,781. Filing ↗machine: t249 · r2 · c19 · span 637172–637179
39Section 08, Daniel P. O'DayDEF 14A2026-03-200001308179-26-000106Section “Director Compensation”. As printed: 0. Filing ↗
40Section 02, Daniel Patrick O'Day 2026-03-27Form 42026-03-300001638643-26-000018Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Johanna Mercier 2026-04-15Form 42026-04-160001782135-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Andrew Dickinson 2026-04-15Form 42026-04-160001310204-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Daniel Patrick O'Day 2026-04-28Form 42026-04-290001638643-26-000020Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Daniel Patrick O'Day 2026-04-28Form 42026-04-290001638643-26-000020Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Ted W. Love 2026-04-30Form 42026-05-040001188919-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Anthony Welters 2026-04-30Form 42026-05-040001213307-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Jeffrey A. Bluestone 2026-04-30Form 42026-05-040000882095-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Kelly A. Kramer 2026-04-30Form 42026-05-040001629885-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Sandra J. Horning 2026-04-30Form 42026-05-040001638709-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Anthony Welters 2026-04-30Form 42026-05-040001213307-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Harish M. Manwani 2026-04-30Form 42026-05-040001527726-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Javier J. Rodriguez 2026-04-30Form 42026-05-040001415548-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Harish M. Manwani 2026-04-30Form 42026-05-040001527726-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Kelly A. Kramer 2026-04-30Form 42026-05-040001629885-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Harish M. Manwani 2026-04-30Form 42026-05-040001527726-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, Javier J. Rodriguez 2026-04-30Form 42026-05-040001415548-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Sandra J. Horning 2026-04-30Form 42026-05-040001638709-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Ted W. Love 2026-04-30Form 42026-05-040001188919-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Jeffrey A. Bluestone 2026-04-30Form 42026-05-040000882095-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Jacqueline K. Barton 2026-04-30Form 42026-05-040001183680-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, Jacqueline K. Barton 2026-04-30Form 42026-05-040001183680-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, Johanna Mercier 2026-05-15Form 42026-05-180001782135-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, Andrew Dickinson 2026-05-15Form 42026-05-180001310204-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, Johanna Mercier 2026-05-15Form 42026-05-180001782135-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, Johanna Mercier 2026-05-15Form 42026-05-180001782135-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
66Section 02, Johanna Mercier 2026-05-15Form 42026-05-180001782135-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
67Section 02, Johanna Mercier 2026-05-15Form 42026-05-180001782135-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
68Section 02, Johanna Mercier 2026-05-15Form 42026-05-180001782135-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
69Section 02, Daniel Patrick O'Day 2026-06-01Form 42026-06-020001638643-26-000022Insider equity transaction reported since the proxy statement. Filing ↗
70Section 02, Daniel Patrick O'Day 2026-06-01Form 42026-06-020001638643-26-000022Insider equity transaction reported since the proxy statement. Filing ↗
71Section 02, Daniel Patrick O'Day 2026-06-01Form 42026-06-020001638643-26-000022Insider equity transaction reported since the proxy statement. Filing ↗
72Section 02, Johanna Mercier 2026-06-10Form 42026-06-110001782135-26-000022Insider equity transaction reported since the proxy statement. Filing ↗
73Section 02, Dietmar Berger 2026-06-10Form 42026-06-110001739515-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
74Section 02, Daniel Patrick O'Day 2026-06-10Form 42026-06-110001638643-26-000024Insider equity transaction reported since the proxy statement. Filing ↗
75Section 02, Andrew Dickinson 2026-06-10Form 42026-06-110001310204-26-000018Insider equity transaction reported since the proxy statement. Filing ↗
76Section 02, Andrew Dickinson 2026-06-10Form 42026-06-110001310204-26-000018Insider equity transaction reported since the proxy statement. Filing ↗
77Section 02, Dietmar Berger 2026-06-10Form 42026-06-110001739515-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
78Section 02, Johanna Mercier 2026-06-10Form 42026-06-110001782135-26-000022Insider equity transaction reported since the proxy statement. Filing ↗
79Section 02, Dietmar Berger 2026-06-10Form 42026-06-110001739515-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
80Section 02, Cain Wettan Keeley M 2026-06-10Form 42026-06-110002110603-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
81Section 02, Cain Wettan Keeley M 2026-06-10Form 42026-06-110002110603-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
82Section 02, Andrew Dickinson 2026-06-10Form 42026-06-110001310204-26-000018Insider equity transaction reported since the proxy statement. Filing ↗
83Section 02, Johanna Mercier 2026-06-10Form 42026-06-110001782135-26-000022Insider equity transaction reported since the proxy statement. Filing ↗
84Section 02, Daniel Patrick O'Day 2026-06-10Form 42026-06-110001638643-26-000024Insider equity transaction reported since the proxy statement. Filing ↗
85Section 02, Daniel Patrick O'Day 2026-06-10Form 42026-06-110001638643-26-000024Insider equity transaction reported since the proxy statement. Filing ↗
86Section 02, Cain Wettan Keeley M 2026-06-10Form 42026-06-110002110603-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
87Section 02, Johanna Mercier 2026-06-15Form 42026-06-160001782135-26-000024Insider equity transaction reported since the proxy statement. Filing ↗
88Section 02, Johanna Mercier 2026-06-15Form 42026-06-160001782135-26-000024Insider equity transaction reported since the proxy statement. Filing ↗
89Section 02, Johanna Mercier 2026-06-15Form 42026-06-160001782135-26-000024Insider equity transaction reported since the proxy statement. Filing ↗
90Section 02, Andrew Dickinson 2026-06-15Form 42026-06-160001310204-26-000020Insider equity transaction reported since the proxy statement. Filing ↗
91Section 02, Daniel Patrick O'Day 2026-07-01Form 42026-07-020001638643-26-000026Insider equity transaction reported since the proxy statement. Filing ↗
92Section 02, Daniel Patrick O'Day 2026-07-01Form 42026-07-020001638643-26-000026Insider equity transaction reported since the proxy statement. Filing ↗
93Section 02, Andrew Dickinson 2026-07-15Form 42026-07-160001310204-26-000022Insider equity transaction reported since the proxy statement. Filing ↗
94Section 02, Johanna Mercier 2026-07-15Form 42026-07-160001782135-26-000026Insider equity transaction reported since the proxy statement. Filing ↗
95Section 06, 2026 voteForm 8-K2026-05-040000882095-26-000008Item 5.07 · say-on-pay result. As reported: 92.19% (votes for as printed: 954,325,805). Filing ↗
96Section 06, 2025 voteForm 8-K2025-05-080000882095-25-000015Item 5.07 · say-on-pay result. As reported: 91.23% (votes for as printed: 929,612,739). Filing ↗
97Section 06, 2024 voteForm 8-K2024-05-090000882095-24-000016Item 5.07 · say-on-pay result. As reported: 92.19% (votes for as printed: 928,702,915). Filing ↗
98Section 01 trend, Δ column (computed)ComputedcomputedΔ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
99Section 03b vehicle mix (computed)ComputedcomputedRSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
100Section 09b board cost (computed)ComputedcomputedCash 982,604 + equity 1,199,456 + all other 61,360 = 2,243,420, summed across the director compensation table rows.machine: formula: Σ = 2,243,420
101Eli Lilly and Company, Section 10b CEO totalDEF 14A2026-03-200000059478-26-000029CEO total compensation as printed in Eli Lilly and Company's own proxy. As printed: 36,698,337. Filing ↗machine: t92 · r2 · c20 · span 925013–925024
102Johnson & Johnson, Section 10b CEO totalDEF 14A2026-03-110000200406-26-000063CEO total compensation as printed in Johnson & Johnson's own proxy. As printed: 32,758,111. Filing ↗machine: r3 · c27 · span 1621235–1621246
103AbbVie Inc., Section 10b CEO totalDEF 14A2026-03-230001104659-26-033387CEO total compensation as printed in AbbVie Inc.'s own proxy. As printed: 32,530,984. Filing ↗machine: t210 · r9 · c26 · span 1414083–1414093
104Gilead Sciences, Inc. (subject), Section 10b CEO totalDEF 14A2026-03-200001308179-26-000106CEO total compensation as printed in Gilead Sciences, Inc.'s own proxy. As printed: 28,437,198. Filing ↗machine: t414 · r1 · c29 · span 989582–989592
105Pfizer Inc., Section 10b CEO totalDEF 14A2026-03-120000078003-26-000033CEO total compensation as printed in Pfizer Inc.'s own proxy. As printed: 27,585,301. Filing ↗machine: t242 · r3 · c12 · span 1506825–1506835
106Amgen Inc., Section 10b CEO totalDEF 14A2026-04-070001193125-26-145588CEO total compensation as printed in Amgen Inc.'s own proxy. As printed: 24,693,120. Filing ↗machine: span 1591156–1591166
107Biogen Inc., Section 10b CEO totalDEF 14A2026-04-280001193125-26-187303CEO total compensation as printed in Biogen Inc.'s own proxy. As printed: 23,646,004. Filing ↗machine: r2 · c16 · span 1174380–1174391
108Bristol Myers Squibb Company, Section 10b CEO totalDEF 14A2026-03-250000014272-26-000006CEO total compensation as printed in Bristol Myers Squibb Company's own proxy. As printed: 21,879,919. Filing ↗machine: t168 · r3 · c15 · span 1302160–1302170
109Vertex Pharmaceuticals Incorporated, Section 10b CEO totalDEF 14A2026-04-020000875320-26-000153CEO total compensation as printed in Vertex Pharmaceuticals Incorporated's own proxy. As printed: 21,144,261. Filing ↗machine: r2 · c13 · span 2942799–2942809
110Merck & Co., Inc., Section 10b CEO totalDEF 14A2026-04-080001193125-26-147704CEO total compensation as printed in Merck & Co., Inc.'s own proxy. As printed: 20,797,845. Filing ↗machine: span 1371012–1371022
111Regeneron Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-240001308179-26-000340CEO total compensation as printed in Regeneron Pharmaceuticals, Inc.'s own proxy. As printed: 7,280,549. Filing ↗machine: r3 · c10 · span 3335980–3335989
112Section 10a, Bristol Myers Squibb Company reciprocityDEF 14A0000014272-26-000006Bristol Myers Squibb Company names Gilead Sciences, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
113Section 10a, Eli Lilly and Company reciprocityDEF 14A0000059478-26-000029Eli Lilly and Company names Gilead Sciences, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
114Section 10a, Pfizer Inc. reciprocityDEF 14A0000078003-26-000033Pfizer Inc. names Gilead Sciences, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
115Section 10a, Vertex Pharmaceuticals Incorporated reciprocityDEF 14A0000875320-26-000153Vertex Pharmaceuticals Incorporated names Gilead Sciences, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
116Section 10a, AbbVie Inc. reciprocityDEF 14A0001104659-26-033387AbbVie Inc. names Gilead Sciences, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
117Section 10a, Amgen Inc. reciprocityDEF 14A0001193125-26-145588Amgen Inc. names Gilead Sciences, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
118Section 10a, Johnson & Johnson reciprocityDEF 14A0000200406-26-000063Johnson & Johnson's most recent proxy was read; its disclosed peer group does not include Gilead Sciences, Inc.. Filing ↗
119Section 10a, Regeneron Pharmaceuticals, Inc. reciprocityDEF 14A0001308179-26-000340Regeneron Pharmaceuticals, Inc. names Gilead Sciences, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
120Section 10a, Merck & Co., Inc. reciprocityDEF 14A0001193125-26-147704Merck & Co., Inc. names Gilead Sciences, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗